Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial

The Lancet Haematology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles